DIAGNOS Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DGNOF research report →
Price Chart
About the company
DIAGNOS Inc. specializes in delivering technology-driven services, with its reach primarily extending across Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. A cornerstone of its offerings is Computer Assisted Retina Analysis (CARA), a web-based software application in the healthcare sector.
- CEO
- Andre Larente
- IPO
- 2003
- Employees
- 22
- HQ
- Brossard, QC, CA
Get TickerSpark's AI analysis on DGNOF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $39.74M
- P/E
- -11.50
- PEG
- -0.83
- P/S
- 873.52
- P/B
- 83.27
- EV/EBITDA
- -14.24
- Div Yield
- 0.00%
- Gross Margin
- -182.42%
- Op Margin
- -6510.52%
- Net Margin
- -6956.84%
- ROE
- 11659.44%
- ROIC
- -204.11%
Latest fiscal year · YoY change
- Revenue
- $65.65K-36.8%
- Gross Profit
- $-119,755+87.3%
- Op Income
- $-4,273,976
- Net Income
- $-4,566,969-6.5%
- EPS
- $-0.04+13.0%
- OCF Growth
- -10.2%
- FCF Growth
- -10.0%
- 52W High
- $0.38
- 52W Low
- $0.13
- 50D MA
- $0.31
- 200D MA
- $0.22
- Beta
- -0.15
- RSI (14)
- 50
- Avg Volume
- 110.02K
No earnings-call transcripts are available for DGNOF yet.
- Free Float
- 95.6%
- Shares Outstanding
- 120.41M
- Float Shares
- 115.10M
Our DGNOF coverage
Recent articles, reports, and earnings notes.
No research on DGNOF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DGNOF report →DIAGNOS Provides an Update on Stock Warrants
globenewswire.com · Oct 6
DIAGNOS Advances Regulatory Strategy with US FDA Submission for CARA System
globenewswire.com · Sep 28
DIAGNOS to Hold its Annual General Meeting of Shareholders on September 30, 2026
globenewswire.com · Sep 14
DIAGNOS Receives Saudi FDA Medical Device License for CARA System, Bringing AI-Assisted Retinal Image Analysis to Saudi Arabia
globenewswire.com · Aug 13
DIAGNOS Receives Health Canada Medical Device Licence for CARA System, Bringing AI-Assisted Retinal Image Analysis to Canadian Optometrists
globenewswire.com · Jul 27
DIAGNOS to Extend the Exercise Period of Stock Warrants
globenewswire.com · Jul 7
Emerging Growth Research Releases Flash Report on DIAGNOS, Highlighting Regulatory Catalysts and Commercialization Potential for CARA AI Platform
globenewswire.com · Jun 5
DIAGNOS to Present at the Emerging Growth Conference on June 10, 2026
globenewswire.com · Jun 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.